Aspira Women’s Health (AWH)
Search documents
Aspira Women's Health Announces $5.5 Million Registered Direct Offering and Concurrent Private Placement
Newsfilter· 2024-01-25 13:00
AUSTIN, Texas, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. ("Aspira" or the "Company") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced that it has entered into definitive agreements with a single healthcare focused institutional investor alongside participation from Nicole Sandford, CEO of Aspira, as well as certain existing shareholders of the Company for the purchase and sale of 1,571,000 share ...
OptimizeRx Announces Strategic Board Changes to Support Growth and Evolving Landscape
Newsfilter· 2024-01-25 12:30
WALTHAM, Mass., Jan. 25, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, is pleased to announce changes to its Board of Directors reflecting a strategic move to further align with the company's growth plans. After nearly a decade of service, Gus Halas is retiring from his position as Chairperson of the Board. During his tenure, he playe ...
Aspira Women’s Health (AWH) - 2023 Q3 - Earnings Call Transcript
2023-11-14 00:37
Aspira Women's Health Inc. (NASDAQ:AWH) Q3 2023 Earnings Call November 13, 2023 4:30 PM ET Company Participants Nicole Sandford - President and Chief Executive Officer Torsten Hombeck - Chief Financial Officer Conference Call Participants Ben Haynor - Alliance Global Partners Operator Good afternoon, ladies and gentlemen, and welcome to the Aspira Women's Health Incorporated Third Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode. Following management's prepared ...
Aspira Women’s Health (AWH) - 2023 Q3 - Quarterly Report
2023-11-12 16:00
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission File Number: 001-34810 Aspira Women's Health Inc. (Exact name of registrant as specified in its charter) | --- | --- | --- | | ...
Aspira Women’s Health (AWH) - 2023 Q2 - Earnings Call Transcript
2023-08-15 01:14
Aspira Women’s Health Inc. (NASDAQ:AWH) Q2 2023 Earnings Conference Call August 14, 2023 4:30 PM ET Company Participants Nicole Sandford – President and Chief Executive Officer Torsten Hombeck – Chief Financial Officer Conference Call Participants Sally Yanchus – Water Tower Research Andrew Brackmann – William Blair Operator Good afternoon, ladies and gentlemen, and welcome to Aspira’s Women’s Health, Incorporated Second Quarter 2023 Earnings Conference Call. At this time, all participants are in listen-onl ...
Aspira Women’s Health (AWH) - 2023 Q2 - Quarterly Report
2023-08-13 16:00
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission File Number: 001-34810 Aspira Women's Health Inc. (Exact name of registrant as specified in its charter) | --- | --- | --- | |----- ...
Aspira Women’s Health (AWH) - 2023 Q1 - Quarterly Report
2023-05-14 16:00
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission File Number: 001-34810 Aspira Women's Health Inc. (Exact name of registrant as specified in its charter) | --- | --- | --- | |---- ...
Aspira Women’s Health (AWH) - 2023 Q1 - Earnings Call Transcript
2023-05-11 22:54
Aspira Women's Health Inc. (NASDAQ:AWH) Q1 2023 Earnings Conference Call May 11, 2023 4:30 PM ET Company Participants Nicole Sandford - President and Chief Executive Officer Ryan Phan - Chief Scientific Officer and Chief Operating Officer Marlene McLennan - Interim Chief Financial Officer Conference Call Participants Sally Yanchus - Water Tower Research Operator Good afternoon ladies and gentlemen and welcome to Aspira Women's Health, Incorporated First Quarter 2023 Earnings Conference Call. During the pres ...
Aspira Women’s Health (AWH) - 2022 Q4 - Annual Report
2023-03-29 16:00
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 ___________________________ FORM 10-K T ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or £ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission file number: 001-34810 Aspira Women's Health Inc. (Exact name of registrant as specified in its charter) Dela ...
Aspira Women’s Health (AWH) - 2022 Q4 - Earnings Call Transcript
2023-03-23 02:49
Aspira Women's Health Inc. (NASDAQ:AWH) Q4 2022 Earnings Conference Call March 22, 2023 4:30 PM ET Company Participants Nicole Sandford - President & Chief Executive Officer Ryan Phan - Chief Scientific Officer & Chief Operating Officer Marlene McLennan - Chief Financial Officer Conference Call Participants Ross Osborn - Cantor Fitzgerald Griffin Soriano - William Blair Operator Good morning ladies and gentlemen and welcome to Aspira Women's Health, Inc. Fourth Quarter and Year-End 2022 Earnings Conference ...